NVCT | Nuvectis Pharma, Inc. Stock Overview

(Stock Exchange: NASDAQ)

Day's Range	8.45 - 9.10
52 Week Range	4.44 - 11.80
Beta	0.79
Implied Volatility	393.57%
IV Rank	23.90%
Day's Volume	132,793
Average Volume	117,103
Shares Outstanding	23,391,499
Market Cap	204,675,616
Sector	Healthcare
Industry	Biotechnology
IPO Date	2022-02-04

Valuation
Profitability
Growth
Health
P/E Ratio	-7.88
Forward P/E Ratio	N/A
EPS	-1.11
1YR Price Target	N/A
Dividend Yield	N/A
Dividend Per Share	N/A
Dividend ExDate	N/A
Dividend PayDate	N/A
Employees	13
Country	USA
Website	NVCT

Nuvectis Pharma, Inc., a biopharmaceutical company, focuses on the development of precision medicines for the treatment of serious unmet medical needs in oncology. It develops NXP800, a novel heat shock factor 1 pathway inhibitor for the treatment of various cancers; and NXP900, a small molecule drug candidate to inhibit the Proto-oncogene c-Src and YES1 kinases. The company was incorporated in 2020 and is based in Fort Lee, New Jersey.

NVCT's peers: CRMD, ETON, FDMT, CMPX, GOSS, HRMY, IMRX, KALV, KNSA, KPTI, KRON, LCTX, LQDA, MDXG, REPL, LYRA, OLMA, LRMR, CNTA, OBIO, GLUE, NAMS, IVA, CGEM, IKNA, AVTE, ELYM, DBTX, ANEB, HOWL, EWTX, CELC, CCCC, SGLY, SRZN, MLEC, ELVN, CVKD

*Chart delayed

Analyzing fundamentals for NVCT we got that it has weak fundamentals where Valuation is considered to be significantly overvalued, Profitability is unacceptably poor, Growth is desperately bad and Health is frighteningly weak. For more detailed analysis please see NVCT Fundamentals page.

Watching at NVCT technicals we can see that long-term trend is bullish, the same as bullish middle-term trend, as well as bullish short-term trend. More technicals details can be found on NVCT Technicals page.